Cellular gene therapy access in Africa: a multifactorial feasibility analysis for implementation
Abstract
Cutting-edge therapeutics, such as cellular and gene therapies, can address critical health care access gaps, improving outcomes for diseases that disproportionately affect individuals living in Africa. Despite the potential to transform health care, financial and clinical infrastructure factors have limited their use. With the potential for better survival rates, improved quality of life, and fewer side effects, is it time to prioritize the development of innovative therapies in Africa? Using CAR T-cell therapies as an exemplar, this study examines whether implementing these therapies is feasible and what strategic shifts are required to make them viable across the continent. With proper clinical infrastructure and expertise, introducing these therapies could drive a medical "leapfrog" phenomenon in African health care, similar to how the telecommunications and mobile banking sectors have rapidly accelerated the continent's development.
Read the paper
Related studies
- Understanding the factors influencing fall armyworm (Spodoptera frugiperda J.E. Smith) damage in African smallholder maize fields and quantifying its impact on yield. A case study in Eastern Zimbabwe
- Alarming situation of emerging H5 and H7 avian influenza and effective control strategies
- Livestock and food security: vulnerability to population growth and climate change
- Atmosphere–ocean oxygen and productivity dynamics during early animal radiations
- Characterization of the global distribution and diversified plasmid reservoirs of the colistin resistance gene mcr-9
- The global seroprevalence of Toxoplasma gondii in pigs: A systematic review and meta-analysis
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.